SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SKK Holdings Ltd. operates as a holding company, which engages in the provision of civil engineering services in subsurface utility works, including power and telecommunication cable laying, water pipeline and sewer rehabilitation works. The company was founded by Chun Seong Ng and Koon Kiat Sze on October 16, 2013 and is headquartered in Singapore.

SKK Holdings Ltd. - Ordinary Shares - Class A

SKK Holdings Ltd

SKK Holdings is experiencing extreme volatility following the announcement of a massive drone asset acquisition, fueling a polarized debate between traders chasing the potential of its thin-float momentum and those warning of significant dilution risks. The stock has become a focal point for day traders and scalpers, drawing intense discussion over its parabolic price swings, the impact of the acquisition on shareholder value, and concerns regarding its long-term stability.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is gaining momentum as community members discuss a potential supply shock driven by active token burns and anticipation surrounding upcoming network developments. Investors are closely monitoring market volume and the large holdings of major exchange figures, fueling speculation about a significant comeback story.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing a significant surge in investor interest and trading volume, driven by positive analyst coverage and high expectations for upcoming Phase 3 clinical data. The community is actively discussing the stock's potential for a major buyout, drawing comparisons to other successful biotech runs as traders focus on the company's proprietary immunotherapy platform and its path toward regulatory filings.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Cns Pharmaceuticals Inc (CNSP) is trending as investors react to a significant private placement financing, with the community actively debating whether the capital raise serves as a validation of the company's oncology pipeline or a precursor to further dilution. Traders are heavily focused on the stock's low-float mechanics, citing potential for high volatility and momentum-driven price action as market participants monitor key technical levels and short-squeeze possibilities.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is currently trending as investors react to the company's announcement of positive biomarker data and its intent to pursue an FDA accelerated approval pathway for its ALS treatment, CNM-Au8. While the community is actively debating the significance of the upcoming Type C meeting and recent insider activity, many are focused on the long-term potential of the company's nanocatalytic platform across various neurodegenerative indications.

Skycorp Solar Group Ltd. is a holding company which designs, develops, manufactures and sells solar PV products and solar power system solutions services, through its indirectly wholly owned subsidiary. Its products include One-stop Solar system, Inverter, LFP Battery, Balcony Storage, and PV Cable. It operates through the following segments: Solar PV Products, High Performance Computing Products, and Others. The Solar PV Products segment includes servers, photovoltaic cable, and photovoltaic connectors. The High Performance Computing Products segment refers to the HPC servers and accessories delivered to the customers. The company was founded on January 19, 2022 and is headquartered in Ningbo, China.

Skycorp Solar Group Ltd. - Ordinary Shares - Class A

Skycorp Solar Group Ltd.

Skycorp Solar Group is experiencing extreme volatility and intense community speculation following news of a strategic acquisition and a private placement, with many traders betting on a short squeeze due to a reported low float and high borrowing fees. While some bulls anticipate a parabolic run toward double-digit price targets, others express caution regarding potential dilution risks and the historical pattern of similar China-based low-float stocks.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant retail interest as traders bet on a potential short squeeze ahead of upcoming earnings, fueled by high short interest and rising borrow fees. The community remains deeply divided, with bulls pointing to strong AI growth narratives and technical breakout potential, while skeptics warn of volatility and caution against over-leveraging on speculative momentum.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending as investors react to a compromise in the CLARITY Act that preserves stablecoin reward programs, fueling renewed optimism for the sector's regulatory path. The community is actively debating the stock's future, weighing the long-term potential of stablecoin infrastructure against short-term volatility and concerns over legislative timing.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors react to hyperscaler earnings reports that confirm a massive, sustained surge in AI infrastructure spending, with the company seen as a primary beneficiary of the industry's compute bottleneck. The community remains focused on the firm's accelerating execution and strategic hyperscaler partnerships, with many discussing its potential to re-rate as a leading independent AI cloud provider.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay shares are trending following an unsolicited buyout proposal from GameStop, sparking heated community debate over the viability of the deal and the potential for significant dilution. Investors are actively questioning the strategic rationale and financing feasibility of the transaction, while simultaneously weighing the impact of activist-led corporate restructuring efforts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Best-Performing ETF Areas of Last Week

Cannabis, semis, crude & hydrogen ETFs led last week as AI momentum, policy boost and Middle East tensions shaped market trends.

In this photo illustration, a Tilray Brands logo is seen displayed on a smartphone and in the background.

Tilray Stock Eyes Breakout Week: Trump’s Cannabis Order Opens Door To US Cancer Market Entry

Trump has also called on Congress to preserve access to full-spectrum CBD products and expand research.

Equity

<ul class="summary-bullets"><li>The change does not legalize marijuana but reduces regulatory hurdles and offers tax relief for licensed operators.</li><li>Trump has earlier framed the move as a step toward supporting medical research, while clarifying that it does not legalize recreational use.</li><li>The DOJ is updating procedures to speed up the rulemaking process needed to move marijuana from Schedule I to Schedule III.</li></ul>Shares of Tilray (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), and IGC Pharma Inc (IGC) remained in focus after the U.S. Department of Justice formally moved to reclassify state-licensed medical marijuana as a less dangerous drug, four months after President Donald Trump signed an executive order to shift it from Schedule I to Schedule III.After rallying in the previous session and gaining in pre-market trading on Thursday, the stocks fell in morning trade. At the time of writing, TLRY, CGC, ACB and IGC fell between 2-5%.&nbsp;Meanwhile, AdvisorShares Pure US Cannabis ETF (MSOS) fell 5.5%.<h2 class="st-heading-2">DOJ To Update Rulemaking Processes For Reclassification</h2>While the change does not legalize marijuana, it reduces regulatory hurdles, offers tax relief for licensed operators, and makes research easier. Schedule III drugs are considered to have a moderate to low risk of dependence. Trump has earlier framed the move as a step toward supporting medical research, while clarifying that it does not legalize recreational use.“This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,”&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana">said</a> Todd Blanche, acting Attorney General, in a statement.Separately, the Justice Department said it is updating procedures to speed up the rulemaking process needed to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. The move is expected to expand access to medical treatments and support research, while also strengthening the legal framework for medical marijuana programs across dozens of U.S. states.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits for TLRY, CGC, ACB, and IGC turned ‘extremely bullish,’ amid ‘extremely high’ message volumes.One user said, “The weed industry is reborn.”<stembedurl>https://stocktwits.com/Lando_Calrissian/message/651131346</stembedurl>Another user said Tilray will be the “king in the U.S. cannabis market.”<stembedurl>https://stocktwits.com/Rumsen/message/651070434</stembedurl>Meanwhile, shares of nano-cap Akanda Corp. (AKAN)&nbsp;climbed 6% higher,&nbsp;extending a stunning 215% surge from the previous session, with investors and traders debating whether the explosive rally is driven by cannabis reclassification optimism or the stock’s low float.Message volumes on the Stocktwits platform for the stock surged by around 48,000% over a 24-hour period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Legalized Marijuana In Canada (Photo by Lane Turner/The Boston Globe via Getty Images)

TLRY, CGC, ACB, MSOS Pare Early Gains After Marijuana Reclassification: Retail Says ‘Weed Industry Is Reborn’

The U.S. Department of Justice formally moved to reclassify state-licensed medical marijuana as a less dangerous drug, four months after President Donald Trump signed an executive order.

AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling

AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling PR Newswire BETHESDA, Md., April 23...

<ul class="summary-bullets"><li>In December, Trump signed an executive order directing the reclassification of marijuana from a Schedule I to a Schedule III drug in the same category as Tylenol with codeine.</li><li>During a separate Oval Office signing ceremony on psychedelics research earlier this month, Trump directly addressed delays in his own rescheduling directive, saying his administration was “slow-walking.”</li><li>A Schedule I drug classification is reserved for substances deemed to have high abuse potential and no accepted medical use such as heroin and LSD.</li></ul> The Trump administration is reportedly slated to move to reclassify marijuana as soon as Wednesday.Axios <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.axios.com/2026/04/22/trump-marijuana-rule-change">reported</a> of the upcoming move, citing an administration official. &nbsp;Shares of Tilray (TLRY) traded 13% higher at the time of writing. Other publicly traded companies in the space including Aurora Cannabis (ACB), Canopy Growth (CGC), and&nbsp; IGC Pharma Inc (IGC) jumped 10%, 20% and 6%, respectively. AdvisorShares Pure US Cannabis ETF (<a href="https://stocktwits.com/symbol/MSOS">MSOS</a>), meanwhile, rallied 23% higher.In December, Trump signed an executive order directing the reclassification of marijuana from a Schedule I to a Schedule III drug in the same category as Tylenol with codeine. The order directed Attorney General to expedite the federal reclassification process through the Drug Enforcement Administration. Trump framed the move as focused on recognizing legitimate medical uses and accelerating research, while explicitly stating it does not legalize recreational marijuana.During a separate Oval Office signing ceremony on psychedelics research earlier this month, Trump directly addressed delays in his own rescheduling directive, saying his administration was “slow-walking.”A Schedule I drug classification is reserved for substances deemed to have high abuse potential and no accepted medical use such as heroin and LSD.The Trump administration is expected to classify marijuana as a Schedule III substance, indicating that it has a lesser potential for abuse and is allowed for use in specific medical treatments, but can also create risks of physical or psychological dependence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TLRY and CGC are trending in the ‘extremely bullish’ territory, coupled with ‘high’ message volume.While <a href="https://stocktwits.com/symbol/TLRY">TLRY stock</a> has gained 70% over the past 12 months, <a href="https://stocktwits.com/symbol/CGC">CGC</a> has gained 16%.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-stock-defies-tornado-setback-with-r2-production-kickstart/cZBBvT3ReGy">RIVN Stock Defies Tornado Setback With R2 Production Kickstart</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

TLRY, CGC, IGC Stocks Light Up On Trump Pot Reclassification Hopes This Week  

Axios reported on Wednesday, citing an administration official, that the Trump administration is slated to reclassify marijuana as soon as Wednesday. 

Top & Flop ETF Areas of 2025 (Revised)

Silver, gold & platinum ETFs (SLVP, SILJ, GOEX) crushed it in 2025, while MEME & VIXY lagged.

Santa Rally Falls Short: Top ETF Performers of December

Santa Rally fizzled as markets stumbled, but ETFs tied to cannabis (MSOS, WEED), metals (SLV, PPLT) and space (UFO) surged.

Top & Flop ETF Areas of 2025

Silver, gold & platinum ETFs (SLVP, SILJ, GOEX) crushed it in 2025, while MSOS, MEME & VIXY lagged amid policy, hype & calm markets.

<ul class="summary-bullets"><li>Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.&nbsp;</li><li>The executive order directs Trump’s administration to initiate the steps needed for the classification shift.</li></ul>Shares of Tilray Brands, Aurora Cannabis and Trulieve Cannabis pulled back on Thursday after an early rally sparked by U.S. President Donald Trump’s executive order to ease federal restrictions on marijuana lost momentum, as investors pared gains following the initial reaction to the policy move.Shares of TLRY and ACB fell 5% and 3% respectively at the time of writing while TCNNF dropped 17%.&nbsp;<h2 class="st-heading-2">Trump Pushes Medical Marijuana</h2>President Donald Trump on Thursday signed an executive order to reschedule marijuana to make it less restrictive and available for “legitimate medical uses.”Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research. Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.“We have people begging for me to do this, people that are in great pain for decades,” Trump said while referring to patients suffering from extreme pain and incurable diseases including cancer. The executive order directs Trump’s administration to initiate the steps needed for the classification shift.“Schedule III status will allow research studies to incorporate real-world evidence and models that can assess the health outcomes of medical marijuana and legal CBD products while focusing on long-term health effects in vulnerable populations like adolescents and young adults,” the White House said in a statement.State regulations on cannabis are currently complex. While a few U.S. states currently permit the recreational use of cannabis, some allow it for medical purposes.<h2 class="st-heading-2">How Did Trump Decide?</h2>According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-18/trump-signs-order-to-reclassify-marijuana-in-industry-win">report</a> from Bloomberg, Trump came to the decision following discussions with Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services Administrator Mehmet Oz as well as cannabis-industry leaders including Trulieve Cannabis Corp CEO Kim Rivers. As per the report, the Centers for Medicare &amp; Medicaid Services is also expected to complete a plan to test making some Medicare patients eligible for therapies derived from cannabinoids.Jazz Pharmaceuticals’ Epidiolex is currently the only drug approved by the U.S. Food and Drug Administration composed of CBD, a psychoactive compound found in cannabis.<h2 class="st-heading-2">Tilray Plans Expansion With Trump’s Push</h2>Tilray, a producer and distributor of medical and adult-use cannabis, subsequently confirmed plans to advance its U.S. medical cannabis operations with the formation of a unit called Tilray Medical USA, Inc. The unit aims to introduce medical-grade cannabis products in targeted therapeutic formats, the company said.“This action [executive order] aligns regulation with a vast body of scientific and medical data supporting cannabis medical use and safety, economic progress, and a healthcare-focused framework, while creating a more credible foundation for medical cannabis research, clinical development, and regulatory clarity,” Tilray CEO Irwin D. Simon said.<h2 class="st-heading-2">Other Cannabis Firms Respond To Policy Change</h2>Cresco Labs applauded the executive order terming it a “cultural turning point” and a “historic shift.” Trulieve too applauded the decision while <a href="https://stocktwits.com/symbol/SMG">Scotts Miracle-Gro</a> expressed support highlighting that 39 states already legalize cannabis in some form. Scotts expects to combine its Hawthorne Gardening company subsidiary, which provides nutrients, lighting and other supplies to legal cannabis growing operations, with a cannabis company in 2026.<a href="https://stocktwits.com/symbol/HITI">High Tide</a> said that it is exploring structures that would allow it to expand its Canna Cabana retail brand into the U.S. through licensing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TLRY">TLRY</a> and <a href="https://stocktwits.com/symbol/CGC">CGC</a> trended in the ‘extremely bullish’ territory at the time of writing. Sentiment around <a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF</a> (MSOS), which tracks American operators, followed suit.TLRY and CGC shares are down 8% and 39% this year, respectively.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-eyes-ex-tesla-employee-sterling-anderson-as-potential-successor-to-ceo-mary-barra-report/cLegDrmRErL">General Motors Eyes Ex-Tesla Employee Sterling Anderson As Potential Successor To CEO Mary Barra: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Tilray, Aurora Cannabis, Trulieve Pull Back After Trump Marijuana Order Rally Runs Out Of Steam

Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research.

Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide, but is instead aimed at improving medical marijuana and cannabidiol research.


Cannabis ETFs Soar Double-Digits on Friday: Here's Why

Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.

Current Price	$4.83
Prev Close	$5.04
Open	$5.00
Dividend Yield	N/A
50-Day Moving Average	$3.99
Beta	N/A
Avg. Volume	12.31M
PE Ratio	N/A

52-Week High	$7.25
52-Week Low	$2.06
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

MSOS
AdvisorShares Pure US Cannabis ETF

Feed

News

Sentiment

Fundamentals

Info

Latest MSOS News

MSOSAdvisorShares Pure US Cannabis ETF